Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27


In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model.

Wang H, Milberg O, Bartelink IH, Vicini P, Wang B, Narwal R, Roskos L, Santa-Maria CA, Popel AS.

R Soc Open Sci. 2019 May 22;6(5):190366. doi: 10.1098/rsos.190366. eCollection 2019 May.


Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer.

Mutonga M, Speedy S, Rademaker A, Liu D, Uthe R, Jain S, Gradishar WJ, Flaum L, Santa-Maria CA.

Breast Cancer Res Treat. 2019 Jul;176(1):95-100. doi: 10.1007/s10549-018-05088-6. Epub 2019 Apr 11.


Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.

Paplomata E, Zelnak A, Santa-Maria CA, Liu Y, Gogineni K, Li X, Moreno CS, Chen Z, Kaklamani V, O'Regan RM.

Clin Breast Cancer. 2019 Jun;19(3):188-196. doi: 10.1016/j.clbc.2018.12.017. Epub 2019 Jan 3.


Immune Checkpoint Inhibitor Therapy in Breast Cancer.

Santa-Maria CA, Nanda R.

J Natl Compr Canc Netw. 2018 Oct;16(10):1259-1268. doi: 10.6004/jnccn.2018.7046. Review.


Obese Breast Cancer Patients and Survivors: Management Considerations.

Sheng JY, Sharma D, Jerome G, Santa-Maria CA.

Oncology (Williston Park). 2018 Aug 15;32(8):410-7.


Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.

Jain S, Shah AN, Santa-Maria CA, Siziopikou K, Rademaker A, Helenowski I, Cristofanilli M, Gradishar WJ.

Breast Cancer Res Treat. 2018 Sep;171(2):371-381. doi: 10.1007/s10549-018-4792-0. Epub 2018 May 30.


A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 Aug;171(1):121-129. doi: 10.1007/s10549-018-4811-1. Epub 2018 May 11.


A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.

Santa-Maria CA, Kato T, Park JH, Kiyotani K, Rademaker A, Shah AN, Gross L, Blanco LZ, Jain S, Flaum L, Tellez C, Stein R, Uthe R, Gradishar WJ, Cristofanilli M, Nakamura Y, Giles FJ.

Oncotarget. 2018 Apr 10;9(27):18985-18996. doi: 10.18632/oncotarget.24867. eCollection 2018 Apr 10.


Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers.

Santa-Maria CA, Kruse M, Raska P, Weiss M, Swoboda A, Mutonga MB, Abraham J, Jain S, Nanda R, Montero AJ.

Breast Cancer Res Treat. 2017 Nov;166(1):179-184. doi: 10.1007/s10549-017-4415-1. Epub 2017 Jul 27.


A pilot study of cabergoline for the treatment of metastatic breast cancer.

Costa R, Santa-Maria CA, Scholtens DM, Jain S, Flaum L, Gradishar WJ, Clevenger CV, Kaklamani VG.

Breast Cancer Res Treat. 2017 Oct;165(3):585-592. doi: 10.1007/s10549-017-4370-x. Epub 2017 Jul 3.


Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.

Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ.

Ann Oncol. 2017 Jan 1;28(1):44-56. doi: 10.1093/annonc/mdw532. Review.


Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.

Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D, Carneiro BA, Chae YK, Cristofanilli M, Gradishar WJ, Giles FJ.

Cancer Treat Rev. 2017 Feb;53:111-119. doi: 10.1016/j.ctrv.2016.12.010. Epub 2017 Jan 5. Review.


Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.

Costa R, Santa-Maria CA, Rossi G, Carneiro BA, Chae YK, Gradishar WJ, Giles FJ, Cristofanilli M.

Oncotarget. 2017 Feb 14;8(7):12417-12432. doi: 10.18632/oncotarget.13778. Review.


Genomic landscape of DNA repair genes in cancer.

Chae YK, Anker JF, Carneiro BA, Chandra S, Kaplan J, Kalyan A, Santa-Maria CA, Platanias LC, Giles FJ.

Oncotarget. 2016 Apr 26;7(17):23312-21. doi: 10.18632/oncotarget.8196.


Manganese Superoxide Dismutase Acetylation and Dysregulation, Due to Loss of SIRT3 Activity, Promote a Luminal B-Like Breast Carcinogenic-Permissive Phenotype.

Zou X, Santa-Maria CA, O'Brien J, Gius D, Zhu Y.

Antioxid Redox Signal. 2016 Aug 20;25(6):326-36. doi: 10.1089/ars.2016.6641. Epub 2016 Apr 15. Review.


Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here?

Santa-Maria CA, Nye L, Mutonga MB, Jain S, Gradishar WJ.

Oncology (Williston Park). 2016 Feb;30(2):148-55. Review.


Neoadjuvant Therapy for Early-Stage Breast Cancer: Current Practice, Controversies, and Future Directions.

Santa-Maria CA, Camp M, Cimino-Mathews A, Harvey S, Wright J, Stearns V.

Oncology (Williston Park). 2015 Nov;29(11):828-38. Review.


Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.

Santa-Maria CA, Blackford A, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge J, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics (COBRA).

Clin Cancer Res. 2016 Mar 15;22(6):1395-402. doi: 10.1158/1078-0432.CCR-15-1213. Epub 2015 Oct 13.


Breast cancer and immunology: biomarker and therapeutic developments.

Santa-Maria CA, Park SJ, Jain S, Gradishar WJ.

Expert Rev Anticancer Ther. 2015;15(10):1215-22. doi: 10.1586/14737140.2015.1086270. Epub 2015 Sep 10. Review.


Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.

Santa-Maria CA, Gradishar WJ.

JAMA Oncol. 2015 Jul;1(4):528-34; quiz 549. doi: 10.1001/jamaoncol.2015.1198. Review.


The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer.

Jain S, Santa-Maria CA, Gradishar WJ.

Oncology (Williston Park). 2015 Jul;29(7):473-8, 481. Review.


Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate.

Korangath P, Teo WW, Sadik H, Han L, Mori N, Huijts CM, Wildes F, Bharti S, Zhang Z, Santa-Maria CA, Tsai H, Dang CV, Stearns V, Bhujwalla ZM, Sukumar S.

Clin Cancer Res. 2015 Jul 15;21(14):3263-73. doi: 10.1158/1078-0432.CCR-14-1200. Epub 2015 Mar 26.


Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index.

Santa-Maria CA, Yan J, Xie XJ, Euhus DM.

Int J Clin Oncol. 2015 Apr;20(2):317-23. doi: 10.1007/s10147-014-0712-4. Epub 2014 Jun 10.


Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of breast cancer management.

Solin LJ, Truong PT, Russo J, Tsuda H, Santa-Maria CA, Wolf AC.

Breast Cancer Manag. 2014 May;3(3):227-228. No abstract available.


Statins and Breast Cancer: Future Directions in Chemoprevention.

Santa-Maria CA, Stearns V.

Curr Breast Cancer Rep. 2013 Sep 1;5(3):161-169.


Complete radiologic response and long-term survival with use of systemic high-dose methotrexate for breast cancer-associated leptomeningeal disease.

Santa-Maria CA, Cimino-Mathews A, Moseley KF, Wolff AC, Blakeley JO, Connolly RM.

Clin Breast Cancer. 2012 Dec;12(6):445-9. doi: 10.1016/j.clbc.2012.07.010. Epub 2012 Sep 24. No abstract available.


Residual risk of breast cancer recurrence 5 years after adjuvant therapy.

Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ.

J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83. doi: 10.1093/jnci/djn233. Epub 2008 Aug 11.

Supplemental Content

Loading ...
Support Center